Boehringer Ingelheim Animal Health is the world's second-largest animal health business, generating $5.5 billion in 2025 sales (+6.5% YoY). The division is anchored by NEXGARD at $1.5 billion in 2025 (+8.5%). Growth is driven by pet parasiticides, poultry vaccines including BULTAVO 3 and VAXXITEK HVT+IBD+H5, and ruminant therapeutics.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Strategic priorities include parasiticide franchise expansion, vaccine pipeline acceleration, and continued investment in companion animal therapeutics. Strengths include diversified revenue across companion and production animals, premier R&D, and global manufacturing. Risks include parasiticide patent cycles, antimicrobial stewardship pressure on livestock, and generic competition.
Topics Covered
• Corporate Overview and History
• Strategic Directions and 2026-2030 Priorities
• Financial Performance and Segment Breakdown
• SWOT Analysis
• Business Segment Analysis
• Technology and Innovation Pipeline
• M&A, Partnerships and Licensing Activity
• Competitive Positioning Against Top 10 Peers
• Strategic Conclusions and Outlook
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Business Segment Analysis
7. Technology and Innovation
8. M&A and Partnerships
9. Competitive Positioning
10. Strategic Conclusions
11. Appendix
List of Tables
Table 1. Boehringer Ingelheim Animal Health — Consolidated Revenue and Operating Income 2021-2025
Table 2. Boehringer Ingelheim Animal Health — Revenue by Segment 2023-2025
Table 3. Boehringer Ingelheim Animal Health — Revenue by Geography 2023-2025
Table 4. Boehringer Ingelheim Animal Health — Top Products by Revenue 2025
Table 5. Boehringer Ingelheim Animal Health — R&D Investment and Pipeline 2023-2025
Table 6. Boehringer Ingelheim Animal Health — M&A and Licensing Activity 2023-2026
Table 7. Boehringer Ingelheim Animal Health — SWOT Analysis Summary
Table 8. Boehringer Ingelheim Animal Health — Competitive Positioning vs. Top 10 Peers
Table 9. Boehringer Ingelheim Animal Health — Capital Allocation 2023-2025
Table 10. Boehringer Ingelheim Animal Health — 2026 Guidance and Strategic Milestones
